In addition, combination therapy with vemurafenib and the EGFR inhibitor panitumumab has shown promising results in early trials of B-RafV600E–positive colon cancer [131] and cotreatment of colon cancer cells with vemurafenib and an EGFR (cetuximab or gefitinib) or Akt (LY294002) inhibitor was synergistic in reducing their growth [13, 132]. This evidence concerns the gene AKT1 and malignant colon neoplasm.